Bambusa Therapeutics Initiated Subcutaneous Dosing
The company has begun dosing the first patient in a Phase 1 clinical trial for its atopic dermatitis treatment.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you believe medical research prioritizes convenient treatment administration for patients with chronic inflammatory skin diseases?
Bambusa Therapeutics has administered the first subcutaneous dose of BBT001 to a patient in New Zealand. The Phase 1 clinical trial is currently enrolling up to 45 patients across the United States, Australia, Europe, and New Zealand to evaluate the safety and activity of the drug.
Why it matters
The study aims to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of BBT001, a bispecific antibody designed to treat moderate-to-severe atopic dermatitis. Successful results could support a transition to Phase 2b and demonstrate the drug's potential for maintenance dosing once every three months.
BBT001 is a bispecific antibody targeting IL-4Rα and IL-31 with an approximate 33-day half-life. Participants in the 12-week study will receive five doses at levels of 360 mg or 720 mg, or a placebo.
The players
Bambusa Therapeutics
This biotechnology company headquartered in Boston specializes in developing bispecific antibodies for dermatological conditions.
The details
The trial evaluates the impact of subcutaneous administration on patients with moderate-to-severe atopic dermatitis. Previous preliminary proof-of-concept results from July 2026 for the intravenous version of the treatment showed EASI improvements of 35.6% at Week 1 and 79.0% at Week 6.
Timeline
July 2026: Bambusa reported preliminary intravenous proof-of-concept results.
October 1, 2026: The company announced the administration of the first subcutaneous dose.
The Tech Race
The transition to subcutaneous delivery for BBT001 mirrors the broader biotech industry effort to increase patient compliance by moving away from clinical-based intravenous administration. This shift positions the drug to compete in the expanding landscape of long-acting treatments for chronic skin conditions.
If successful, the development of BBT001 could eventually provide patients with a maintenance dosing schedule of just once every three months. This potential shift would significantly reduce the treatment burden for individuals currently managing moderate-to-severe atopic dermatitis.
The takeaway
The move to subcutaneous dosing represents a critical step in assessing the practical, long-term therapeutic utility of this bispecific antibody. Researchers will now monitor the trial to determine if the drug sustains the high clinical improvement rates observed in initial intravenous testing.
Further reading
Learn more about the latest innovations in clinical development in the Biotech section.
More information
For additional corporate information, visit the Bambusa Therapeutics corporate website.
Live Poll
Do you believe medical research prioritizes convenient treatment administration for patients with chronic inflammatory skin diseases?
